GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 29, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today detailed its presence at the EASL Congress™ 2024. GENFIT accelerates its research in Acute on-Chronic Liver Failure (ACLF) EF CLIF and GENFIT partnership event GENFIT will co-host an event with the European Foundation for the Study of Chronic L ...